Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests

v3.21.1
Non-Controlling Interests
3 Months Ended
Mar. 31, 2021
Non-Controlling Interests  
Non-Controlling Interests

12. Non-Controlling Interests

Non-controlling interests in consolidated entities are as follows:

    

    

For the three months ended

    

    

    

    

 

As of March 31, 2021

March 31, 2021

As of March 31, 2021

 

Net loss attributable to

Non-controlling interests

Non-controlling

 

($ in thousands)

    

NCI equity share

non-controlling interests

in consolidated entities

ownership

 

FBIO Acquisition Corp VIII

$

(99)

 

(28)

$

(127)

 

24.0

%

Aevitas

(3,874)

 

(318)

 

(4,192)

 

46.0

%

Avenue 2

 

1,915

 

(773)

 

1,142

 

77.4

%

Baergic

 

(1,838)

 

(12)

 

(1,850)

 

39.5

%

Cellvation

 

(1,313)

 

(39)

 

(1,352)

 

22.1

%

Checkpoint 1

 

48,130

 

(4,588)

 

43,542

 

80.4

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

(1,033)

 

(478)

 

(1,511)

 

29.8

%

Helocyte

 

(5,210)

 

(53)

 

(5,263)

 

18.3

%

JMC

 

1,076

 

35

 

1,111

 

12.0

%

Mustang 2

 

119,322

 

(10,862)

 

108,460

 

81.3

%

Oncogenuity

(507)

 

(128)

 

(635)

 

25.3

%

Tamid

 

(712)

 

 

(712)

 

22.8

%

Total

$

155,567

$

(17,244)

$

138,323

 

  

    

For the twelve months ended

    

    

 

As of December 31, 2020

December 31, 2020

As of December 31, 2020

 

Net loss attributable to 

Non-controlling interests 

Non-controlling 

 

($ in thousands)

    

NCI equity share

    

non-controlling interests

    

 in consolidated entities

    

 ownership

 

FBIO Acquisition Corp VIII

$

(7)

(27)

$

(34)

 

10.0

%

Aevitas

(2,370)

(823)

 

(3,193)

 

39.0

%

Avenue 2

 

5,800

(3,974)

 

1,826

 

77.4

%

Baergic

 

(1,662)

(97)

 

(1,759)

 

39.5

%

Cellvation

 

(1,089)

(182)

 

(1,271)

 

22.1

%

Checkpoint 1

 

41,704

(13,265)

 

28,439

 

80.4

%

Coronado SO

 

(290)

 

(290)

 

13.0

%

Cyprium

 

567

(1,478)

 

(911)

 

30.5

%

Helocyte

 

(4,986)

(259)

 

(5,245)

 

18.8

%

JMC

 

138

491

 

629

 

7.1

%

Mustang 2

 

116,060

(36,429)

 

79,631

 

80.9

%

Oncogenuity

(82)

(376)

 

(458)

 

25.3

%

Tamid

 

(663)

(40)

 

(703)

 

22.8

%

Total

$

153,120

$

(56,459)

$

96,661

 

Note 1:

Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Note 2:

Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.